Medpace Holdings, Inc. (MEDP)

Market Cap	15.08B +68.3%
Revenue (ttm)	2.78B +24.7%
Net Income	491.50M +17.5%
EPS	17.06 +26.8%
Shares Out	28.56M
PE Ratio	30.96
Forward PE	30.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	523,068
Open	531.21
Previous Close	531.67
Day's Range	525.17 - 536.29
52-Week Range	373.00 - 628.92
Beta	1.15
Analysts	Hold
Price Target	472.33 (-10.56%)
Earnings Date	Jul 22, 2026

About MEDP

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data man...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Aug 11, 2016
• Employees: 6,200
• Stock Exchange: NASDAQ
• Ticker Symbol: MEDP
• Website: https://www.medpace.com

Financial Performance

In 2025, Medpace Holdings's revenue was $2.53 billion, an increase of 19.97% compared to the previous year's $2.11 billion. Earnings were $451.12 million, an increase of 11.57%.

Analyst Summary

According to 13 analysts, the average rating for MEDP stock is "Hold." The 12-month stock price target is $472.33, which is a decrease of -10.56% from the latest price.

Price Target

$472.33

(-10.56% downside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jul 23, 2026

Data Sources Report a data error